癌治療における放射線増感剤の影響に関する実験的研究 : 特に 5-Bromodeoxyuridine について

概要

論文の詳細を見る
In radiotherapy, much radiation is sometimes required for curing malignant tumors. In these cases, not only the tumor cells but also healthy ones surrounding them are often damaged. So, in order to achieve the greatest effect with least application of radiation without affecting the healthy tissue, a radiation-sensitizing agent is clinically used at the same time. To investigate the effects of 5-Fu and BUdR in particular among others as radiation-sensitizing agents macroscopically and histopathologically, I made 122 experiments as to VX2 Carcinoma, experimental solid tumors transplanted hypodermically in the calves of the hind legs of rabbits. Experimental groups and contrast groups are divided into six as follows. A : None treatment. B : 5-Fu infusion. C : BUdR+Antimetabolite infusion. D : Radiation. E : 5-Fu infusion and radiation. F : BUdR+Antimetabolite infusion and radiation. Based on the preliminary experiment data, the amount of agent given is 5 mg/kg/day in 5-Fu and 50 mg/kg/day in BUdR, and the amount of radiation is 300 rad/day in each case. 5-Fu is used as Antimetabolite and its amount is one-tenth 5-Fu Infusion Group. The agent and the radiation are given for five days. The summary of the results is as follows : 1. In the 300 rad/day Group, the recovery from radio-injury is histopathologically observed since the third day after treatment. The amount of radiation is not enough to result in a complete cure. 2. In the two Agent Infusion Group, 5-Fu and BUdR+Antimetabolite proved to be anti-cancer, but neither of them lessen tumor itself nor their anti-cancer property result in effective treatment. 3. In the 5-Fu Infusion and Radiation Group, little difference is found macroscopically between this group and Radiation Group, but the histopathological observations on the third and seventh days after treatment show a strong degenerative change in the tumor cell and radiosensitive effect by 5-Fu. But the tumor is not lessened. 4. In the BUdR+Antimetabolite Infusion and Radiation Group, apart from the other groups, the tumor begins to reduce on the third day, and on the seventh and fourteenth days, necrosis of the greater part of tumor is seen and the rest of the tumor cells is found to be in degenerative change. And on the twenty first day after treatment, no live tumor cell is found and only dead remains of tumor cells are found. The results are confirmed both macroscopically and histopathologically. The process of its cure is as follows : degeneration-necrosis-absorption-granulation tissue-fibrosis. 5. BUdR, remarkable for its radiation-sensitization, can be expected to show its effectiveness in the clinical application to oral malignant tumors which are mostly squamous cell carcinoma.
九州歯科学会の論文
1975-11-30

癌治療における放射線増感剤の影響に関する実験的研究 : 特に 5-Bromodeoxyuridine について

スポンサーリンク

概要

著者

関連論文

スポンサーリンク